Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Fallopian Tube Cancer Clinical Trials

A listing of Fallopian Tube Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (15) clinical trials

DEC-205/NY-ESO-1 Fusion Protein CDX-1401 Poly ICLC and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian Fallopian Tube or Primary Peritoneal Cancer in Remission

PRIMARY OBJECTIVES: I. To determine the safety of fixed doses of DEC205mAb-NY-ESO-1 fusion protein (DEC-205/NY-ESO-1 fusion protein CDX-1401) with adjuvant poly-ICLC given as a vaccine in combination with INCB024360 (IDO1 inhibitor INCB024360). (Phase I) II. To evaluate toxicity as defined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse ...

Phase

Ruxolitinib Phosphate Paclitaxel and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer

PRIMARY OBJECTIVES: I. Determine whether treatment with ruxolitinib in combination with conventional neoadjuvant and post-surgical chemotherapy is safe and tolerable in the primary therapy for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. (Phase I) II. Demonstrate whether treatment with ruxolitinib in combination with conventional neoadjuvant and post-surgical chemotherapy results ...

Phase

Olaparib Durvalumab and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

PRIMARY OBJECTIVES: I. To assess the safety and toxicity of the combination of PARP inhibitor olaparib with anti-PD-L1 antibody durvalumab and anti-CTLA4 antibody tremelimumab. (Phase I) II. To assess the impact of the combination of olaparib with durvalumab and tremelimumab on progression free survival (PFS) rates. (Phase II) SECONDARY OBJECTIVES: ...

Phase

LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer

The concept of molecular profiling leading to personalised medicine is based on the hypothesis that using treatments selected by a molecular profiling approach favourably changes the clinical course for an individual patient. In order to best determine the next steps in a particular patient's clinical course, it is necessary to ...

Phase

Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer

Long-term survival in stage IV serous ovarian, peritoneal, and fallopian tube cancer is poor and has not significantly improved over the last decades. Standard treatment consists of debulking surgery and six courses of carboplatin and paclitaxel. Nevertheless, the disease recurs in >90% of women, usually within two years. Since early ...

Phase

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer

Ovarian cancer (OC) remains the most lethal gynecologic malignancy owing to late detection, intrinsic and acquired chemo-resistance and remarkable heterogeneity. There is an unmet medical need to develop new therapy modalities. In preclinical studies, GL-ONC1, has shown the ability to preferentially locate, colonize and destroy tumor cells in more than ...

Phase

Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial Ovarian Fallopian Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

This trial is a Phase 1b/2a trial designed to evaluate the safety and efficacy of adding oral AL3818 to standard platinum-based chemotherapy such as carboplatin plus paclitaxel, concurrently and continued as a maintenance therapy for up to 12 months, in subjects with recurrent or metastatic endometrial, ovarian, fallopian, primary peritoneal, ...

Phase

Pazopanib Hydrochloride Paclitaxel and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer Fallopian Tube Cancer or Peritoneal Cancer

OBJECTIVES Primary To determine the maximum-tolerated dose of pazopanib hydrochloride in combination with paclitaxel and carboplatin in patients with platinum-refractory or -resistant ovarian epithelial, fallopian tube, or peritoneal carcinoma. (Phase I) To determine the progression-free survival (PFS) at 1 year according to the RECIST 1.1 in these patients. (Phase II) ...

Phase

Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer Fallopian Tube Cancer or Primary Peritoneal Cavity Cancer

OBJECTIVES: Primary - Determine the safety and tolerability of combination therapy comprising phenoxodiol and docetaxel in patients with recurrent or persistent advanced ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer. Secondary - Determine the effect of phenoxodiol on the toxicity of docetaxel using a weekly treatment regimen. - Determine ...

Phase

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer

Study Groups: This study has 2 parts: a safety lead-in and Phase 2. If you are found to be eligible to take part in this study, you will be assigned to either the Safety Lead-in or the Phase 2 portion, depending on when you join the study. Up to 12 ...

Phase